Presumptive Ivermectin Timing Against a Vision-Threatening Steroid Start
A vision-threatening flare of giant cell arteritis needs immediate high-dose steroids in a patient whose decades in a strongyloides-endemic region make that same treatment dangerous without care taken in the same visit.
Carmen L., a 68-year-old woman, spent nearly two decades doing public-health and vaccination outreach in rural highland Guatemala before returning to the United States for good thirty years ago, a chapter of her life she still talks about more than any other. She is otherwise healthy, with no other major medical history, and came to the emergency department this morning after four days of a new, severe headache localized over her right temple, jaw pain that worsens with chewing, and — this morning — a curtain of vision loss in her right eye that resolved after about ten minutes but left her frightened enough to come in immediately.
Her exam and history are close to textbook for GCA — temporal headache, jaw claudication, a transient monocular vision event that, if it recurs and doesn't resolve, threatens permanent blindness within hours to days — and her ESR of 88 sits far enough above the 50 the classification criteria use as a threshold that there is no diagnostic ambiguity left to resolve before treating. High-dose glucocorticoids are the only therapy that reliably prevents that outcome, and the standard of care is to start them immediately, before biopsy confirmation, given how much vision is on the line. Her decades in a strongyloides-endemic region are the complication: intestinal strongyloidiasis can persist for a lifetime through its own internal autoinfective cycle even decades after the original exposure ended, usually kept in check by an intact eosinophil-mediated immune response — the same response high-dose corticosteroids specifically suppress. Losing that check is what converts an otherwise low-grade, often asymptomatic chronic infection into hyperinfection syndrome, with larvae disseminating beyond the gut into the lungs, bloodstream, and central nervous system. Keiser and Nutman's review of strongyloidiasis in immunocompromised hosts puts mortality above fifty percent once dissemination is established, and identifies corticosteroids — specifically, more consistently than any other immunosuppressant — as the drug exposure most often preceding it.
The epidemiology here is easy to underweight precisely because it's invisible on today's exam: strongyloides causes little or no symptom burden in most chronically colonized hosts, which is exactly why decades can pass without anyone thinking to test for it, and why it surfaces clinically only at moments like this one, when an unrelated diagnosis demands the one intervention the parasite has been waiting for. Her case is not an unusual one for the population it represents — longtime residents and aid workers returning from endemic regions are disproportionately represented in reported hyperinfection case series, not because their risk is exotic, but because their exposure window was simply long enough for chronic colonization to take hold before anyone left the region where it happened.
Two prescriptions that have to leave the pharmacy at the same time
High-dose prednisone starts now, in this department, before she leaves for anywhere else. Giant cell arteritis with a vision event is one of the genuine same-hour emergencies in rheumatology — every hour of untreated arteritis is another hour of real risk that the next episode doesn't resolve in ten minutes. I don't want anything, including a strongyloides workup, to be the reason her first dose goes in twenty minutes later than it has to.
I'm not asking for a delay — I'm asking for the ivermectin to leave the pharmacy in the same window as the prednisone, not sometime later today once someone remembers to order it.
The urgency argument you're making for steroids is exactly the argument for treating her strongyloides risk simultaneously, not sequentially: it's the steroids themselves that disable the eosinophil response keeping a chronic infection contained, so the danger window opens the moment the first prednisone dose is absorbed, not whenever ivermectin eventually gets started. Waiting for serology to confirm infection before treating isn't a safe default here — turnaround is days, hyperinfection can begin within that same window, and single-dose ivermectin's own safety profile in someone without confirmed infection is favorable enough that treating presumptively, based on her exposure history alone, is the correct trade regardless of what the serology eventually shows. Keiser and Nutman's series is the one I keep coming back to on this: corticosteroids are the exposure that shows up again and again ahead of dissemination, more consistently than any other, and we are about to give her a lot of one.
Agreed and executed within the same visit: high-dose oral prednisone and a single presumptive dose of ivermectin given together, before she left the emergency department, rather than treating the strongyloides question as a follow-up item. Serology sent for documentation and to guide whether a second ivermectin dose is needed once results return.
One point flagged rather than fully resolved: how this should be handled for a patient with a much older, vaguer exposure history — a single childhood visit somewhere endemic, say, rather than two decades of residence. Both agreed her case was clear-cut; neither offered a firm answer for where the exposure-history threshold for presumptive treatment should actually sit.